/
DNA
$10.21-$0.04 (-0.39%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$669.6M
65M shares
52-week range
$5.37 – $17.58
40% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NYSE
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-476.99
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $54.2M | $76.7M | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Cost of revenue | $0 | $15.6M | $129.7M | $204.2M | $54.0M | $38.5M | $31.5M |
| Gross profit | $54.2M | $61.0M | $184.1M | $273.5M | $197.4M | $188.5M | $138.6M |
| Gross margin | 100.0% | 79.6% | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| R&D | $96.3M | $159.8M | $1.15B | $1.05B | $580.6M | $424.1M | $243.8M |
| Operating income | −$71.6M | −$137.0M | −$1.83B | −$2.21B | −$864.4M | −$559.8M | −$315.3M |
| EBITDA | −$106.7M | −$108.6M | −$1.81B | −$2.06B | −$821.3M | −$484.4M | −$254.6M |
| Net income | −$119.3M | −$126.6M | −$1.83B | −$2.10B | −$892.9M | −$547.0M | −$312.8M |
| Net margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (diluted) | -4.15 | -4.00 | -55.53 | -50.20 | -18.40 | -10.54 | -5.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $106M | $-3.91 | $-3.99–$-3.83 | 1 |
| 2027 | $116M | $-3.31 | $-3.38–$-3.23 | 1 |
| 2028 | $296M | $-3.18 | $-3.25–$-3.11 | 1 |
| 2029 | $369M | $-2.24 | $-2.29–$-2.19 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
www.ginkgobioworks.com- Employees
- 485
- IPO / List date
- Apr 19, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds DNA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 100,456 | $615.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-20 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded DNA yet.
